CADD

Photonic Hires Global Quantum Leaders in Key Leadership Roles

Retrieved on: 
Thursday, May 2, 2024
Other Health, Research, Networks, Hardware, Technology, Semiconductor, Security, Science, Engineering, Manufacturing, Telecommunications, Health, University, Materials science, Fortune 500, Physics, Simon Fraser University, Jennewein, Silicon, Arena, Communication, SanDisk, Kazan Federal University, CERC, Intel, Chemistry, CADD, Institute of technology, Quantum, Marketing, Applied Materials, MBA, Inc., Architecture, Finnie, Microscope

“Photonic has searched extensively for the right talent to help us achieve our ambitious goals.

Key Points: 
  • “Photonic has searched extensively for the right talent to help us achieve our ambitious goals.
  • “The quantum industry is starting to recognize the need for distributed quantum capabilities.
  • In the areas of research and development, materials science, and quantum networks:
    Dr. Chantal Arena joins as vice president of research, development, and production – devices.
  • As a Canada Excellence Research Chair (CERC), and scientific lead for the Quantum EncrYption and Science Satellite (QEYSSat) – Canada’s first quantum communication satellite – Jennewein informs the company’s quantum networking strategy.

Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform

Retrieved on: 
Wednesday, April 3, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Cloud, Google Cloud, Algorithm, Database, Drug discovery, Drug, CADD, DMTA, AI, Assay, Confidentiality, Therapy, Machine learning, Medical device

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.

Key Points: 
  • Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
  • Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application.
  • The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points.
  • Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, “We are committed to continually advancing our service experience and providing innovative end-to-end solutions to our global partners.

Infrasense Scans Interstate Bridge Deck Approach Slabs using 3D Ground Penetrating Radar (3DGPR) to Identify Areas of Voiding

Retrieved on: 
Tuesday, January 16, 2024
Data analysis, GPS, Software, WATSON, Examiner, Anomaly, CADD, Road

WATSON, Ind., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Infrasense, a pioneering leader in non-destructive infrastructure evaluation, announces the successful completion of a comprehensive void analysis project for four select bridges on a tollway in Indiana.

Key Points: 
  • Infrasense uses cutting-edge 3D Ground Penetrating Radar (3DGPR) technology to identify voids under approach slabs across bridges along a tollway in Indiana.
  • The project's primary objective was the precise identification of voids in the approach slabs of the bridges.
  • The software facilitated the stitching of collected data files and enabled comprehensive analysis of approach slabs.
  • Quantitative Voiding Assessment: The analysis resulted in the identification of voiding activity across the slabs, with detailed quantities provided to the client.

Kelly Engineering Named a Contingent Staffing Leader by Everest Group

Retrieved on: 
Tuesday, September 19, 2023
CADD, Learning, Telecom, PEAK, John Kelly (engineer), National Academy of Engineering, Investment, Matrix, DEI, Kelly, Interior design, Consultant, Management, Science, Engineering, TROY

TROY, Mich., Sept. 19, 2023 /PRNewswire/ -- Kelly Engineering has been named a Leader on Everest Group's U.S. Contingent Staffing PEAK Matrix®. Among the engineering staffing providers assessed by Everest Group, Kelly earned the highest marks for vision and capability, which measure its ability to deliver services to clients successfully.

Key Points: 
  • Business recognized for its specialist approach, technology investments, and managed services
    TROY, Mich., Sept. 19, 2023 /PRNewswire/ -- Kelly Engineering has been named a Leader on Everest Group's U.S.
  • Among the engineering staffing providers assessed by Everest Group, Kelly earned the highest marks for vision and capability, which measure its ability to deliver services to clients successfully.
  • This combined has helped position it as a Leader on Everest Group's U.S. Engineering Contingent Talent and Strategic Solutions PEAK Matrix® Assessment 2023," Everest Group Vice President Priyanka Mitra said.
  • "We are proud to be the experts at hiring experts and to be recognized by Everest Group among the best contingent staffing providers in the country."

OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs

Retrieved on: 
Tuesday, September 12, 2023
Software, Research, Pharmaceutical, Hardware, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, Drug, CADD, Biologically based mental illness, Deep learning, CHARMM, Movement, UCB, Protein, Student, Patient, Machine learning, Dassault Systèmes, Drug discovery, Recursion, Physics, Artificial intelligence, Biology, Therapy, Neurology, Medical device, Pharmaceutical industry, Bayer, NVIDIA

UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium.

Key Points: 
  • UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium.
  • “AI as applied to proteins is one of the most promising areas for AI to have an impact on our day-to-day lives.
  • “Valence Labs is honored to join OpenFold and excited to contribute to the growing movement of democratizing machine learning research for the drug discovery community,” said Daniel Cohen, President of Valence Labs.
  • “Valence has a strong legacy of sharing our research and tools with the machine learning community, and we look forward to accelerating those efforts through the OpenFold consortium.”

Groundbreaking 3D Monitor Developed for Medical, Engineering, Design and Gaming

Retrieved on: 
Thursday, September 7, 2023
Holo, Metaverse, SBS, CADD, Ethernet, Communication, Research and development, Wi-Fi, NFT, OpenGL, Unity, 3D, Eye, CAD, Android, Laparoscopy, Endoscopy, Doctor of Philosophy, Development, CPU, OpenXR, Ophthalmology, SDK, Digital, FPGA, AR, GPU, Software, Satellite navigation device, Television, Video game, Engineering

MIAMI, Sept. 7, 2023 /PRNewswire/ -- IQH3D introduces the first high-performance 4K 15.6" 3D lenticular screen with Artificial-Intelligence-driven optical eye-tracking capabilities and an embedded dedicated FPGA board for better 3D image quality and faster visual response. This Glasses-Free 3D Monitor will range in size from 15.6 inches to 32 inches and is specifically designed for medical, gaming and design applications.

Key Points: 
  • This Glasses-Free 3D Monitor will range in size from 15.6 inches to 32 inches and is specifically designed for medical, gaming and design applications.
  • The monitor is also great for gaming, Metaverse 3D modeling, design platforms, and film and special effects animation.
  • The monitor is also great for gaming, Metaverse 3D modeling, design platforms, and film and special effects animation.
  • Their team includes software and hardware integrators to simplify the transition from 2D or headgear-required 3D to Glasses-Free 3D.

New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide

Retrieved on: 
Sunday, January 22, 2023
PGM, Protein, Drug discovery, Automation, MD, NGS, Science, Disease, CADD, Patient, AI, Software, Database, MAHA, STB, Software as a service, Pharmaceutical industry, Medical device

Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates

Key Points: 
  • Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates
    Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide.
  • Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology.
  • By integrating DeepMatcher®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system.
  • Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources.

New cloud platform 'STB CLOUD' disrupts AI Drug discovery worldwide

Retrieved on: 
Sunday, December 18, 2022
Protein, Drug discovery, STB, Software, Science, PGM, MD, CADD, Database, Disease, MAHA, AI, Automation, Software as a service, NGS, Patient, Pharmaceutical industry, Medical device

Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates

Key Points: 
  • Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates
    Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide.
  • Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology.
  • By integrating DeepMatcher®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system.
  • Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources.

Smiths Medical Issues Urgent Medical Device Correction Letter Notifying Customers of Potential Issues with CADD™ Infusion System Infusion Sets for use with CADD pumps

Retrieved on: 
Monday, December 12, 2022
CADD, Letter, Patient, Sale, NDA, Medical device

MINNEAPOLIS, Dec. 12, 2022 /PRNewswire/ -- Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of two potential issues with CADDTM Infusion System Infusion Sets related to potential lack of delivery or underdelivery and false no disposable attached (NDA) alarms.

Key Points: 
  • MINNEAPOLIS, Dec. 12, 2022 /PRNewswire/ -- Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of two potential issues with CADDTM Infusion System Infusion Sets related to potential lack of delivery or underdelivery and false no disposable attached (NDA) alarms.
  • The letter details the issues, the affected items, the required steps to perform, and specific instructions for treatment of patients requiring life sustaining therapy.
  • This may result in underdelivery or non-delivery of medication, despite the pump displaying that the infusion is running properly.
  • The second issue, false "no disposable attached" (NDA) alarms, is specific to CADD-Legacy pumps, which Smiths Medical announced the discontinuation of sale effective December 31, 2022.

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

Retrieved on: 
Friday, December 2, 2022
Dai, Peptide, Focus X, Full Life Christian Centre, CADD, CMC, Cryogenic electron microscopy, PCC, Radiopharmaceutical, Trust, Chemical substance, IIT, Therapy, Cancer, Research, ASMS, CSO, HDX, EFS, Toxicity, DNA, Patient, Acquisition, Euler's totient function, SPR, Head, Control, CIO, Antibody, Drug, PDC, Pharmaceutical industry, Fine chemical, Manufacturing

They completed their angel round in the third quarter of 2020, which was led by Viva.

Key Points: 
  • They completed their angel round in the third quarter of 2020, which was led by Viva.
  • In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
  • Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
  • Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.